Understanding USP Standards for Med Spas and Supplement Distributors

The United States Pharmacopeia (USP) publishes the standards that define quality for pharmaceutical preparations. For med spas and supplement distributors working with peptide APIs, three chapters are particularly relevant: USP <795> for non-sterile preparations, USP <797> for sterile preparations, and USP <800> for hazardous drug handling.

USP <797> is the most relevant for peptide preparation, as many peptide treatments are administered by injection and therefore require sterile conditions. The revised chapter (effective November 2023) introduces stricter requirements for personnel training, environmental monitoring, and beyond-use dating (BUD) that directly impact how med spas handle peptide APIs.

The revised USP <797> categorizes compounded sterile preparations (CSPs) based on the conditions under which they are compounded and the time within which they will be used. Category 1 CSPs are assigned shorter BUDs and have less stringent requirements, while Category 2 CSPs allow longer BUDs but require more rigorous environmental controls, personnel qualifications, and quality assurance activities. Most peptide preparations intended for multi-dose, patient-specific use will fall into Category 2, meaning compounders must meet the full range of requirements for environmental monitoring, media fill testing, and stability documentation.

Personnel training and qualification under the revised USP <797> is more rigorous than many facilities had previously implemented. Personnel handling sterile peptide preparations must demonstrate competency through didactic training, practical skills assessment, and media fill testing (also known as aseptic technique qualification). For med spas preparing peptide treatments, this training should also address peptide-specific handling considerations such as proper reconstitution technique, sensitivity to mechanical stress (avoid vigorous shaking), and the importance of protecting light-sensitive peptides from prolonged exposure.

Under USP <797>, facilities handling sterile peptide preparations must ensure that all components — including peptide APIs — come from FDA-registered suppliers with documented quality programs. The API's COA must confirm identity, purity, and potency, and the facility must have procedures for verifying these documents before using the material in treatments.

The requirement for FDA-registered suppliers has important practical implications for peptide API sourcing. Not all peptide API manufacturers are FDA-registered, particularly those based outside the United States. Med spas and supplement distributors must verify registration status through the FDA's Drug Establishment Current Registration Site (DECRS) database and should be aware that registration status can change. Periodic re-verification — at least annually — should be built into your supplier qualification process. oriGENapi maintains current registration status information for all suppliers in its network, providing an additional verification layer.

Environmental monitoring under the revised USP <797> requires viable and non-viable air sampling, surface sampling, and personnel sampling at defined frequencies. For med spas preparing sterile peptide treatments, this means investing in environmental monitoring equipment, establishing alert and action levels, and documenting corrective actions when monitoring results exceed these levels. The cost and complexity of environmental monitoring is a significant reason why some facilities are choosing to focus on Category 1 preparations or partner with outsourcing facilities for sterile peptide treatments.

Beyond-use dating for peptide preparations requires stability data that may need to come from the API manufacturer or be generated through pharmacy-specific testing. Peptides are generally less stable than small-molecule drugs, making accurate BUD assignment critical for patient safety.

Stability testing for peptide preparations is an area where many facilities struggle. The revised USP <797> is more prescriptive about the data required to support extended BUDs. For peptide preparations, stability-indicating analytical methods — typically HPLC with UV detection — are necessary to distinguish between intact peptide and degradation products. Facilities that lack in-house analytical capabilities may need to contract with third-party laboratories for stability studies. When sourcing peptide APIs, ask manufacturers about the availability of stability data for the API itself and for common formulations, as this data can significantly simplify your BUD assignment process.

USP <800> may also apply if any of the peptide APIs you handle are classified as hazardous drugs. While most therapeutic peptides are not on the NIOSH hazardous drug list, some cytotoxic peptides and certain hormonal peptides may require handling under <800> protocols.

The intersection of USP <800> with peptide handling is a nuanced area. Even if a specific peptide is not on the NIOSH list, the facility must conduct its own assessment of occupational exposure risk. Some peptide APIs with potent pharmacological activity at low doses may warrant containment precautions similar to those required under <800>, even if not formally classified as hazardous. Your risk assessment should consider the peptide's mechanism of action, potency, route of exposure risk during handling, and any available occupational exposure limit (OEL) data. Document your hazard assessment process and review it whenever you add a new peptide to your formulary.

USP <795>, while focused on non-sterile preparations, is relevant for med spas that prepare non-sterile peptide formulations such as topical creams or nasal sprays. The revised <795> introduces requirements for master formulation records, preparation records, and quality control that parallel those in <797>. For non-sterile peptide preparations, key considerations include ensuring uniform distribution of the peptide API in the final preparation, verifying compatibility between the peptide and excipients, and assigning appropriate BUDs based on stability characteristics.

Maintaining compliance with USP standards requires a systematic approach to vendor qualification, incoming material verification, environmental monitoring, and documentation. Digital platforms that automate these processes can help med spas and supplement distributors maintain continuous compliance while reducing the administrative burden on practitioners and staff.

The investment in USP compliance infrastructure pays dividends beyond regulatory adherence. Med spas and supplement distributors that can demonstrate robust compliance with USP standards build trust with providers, gain confidence from patients, and differentiate themselves in a competitive market. As regulatory expectations continue to increase, businesses that have already built strong compliance foundations will find it easier and less costly to adapt to new requirements, while those that have deferred compliance investments will face increasingly expensive catch-up efforts.